Janus Henderson Group PLC Reduces Stock Position in Enovis Co. (NYSE:ENOV)

Janus Henderson Group PLC lowered its position in shares of Enovis Co. (NYSE:ENOV - Free Report) by 10.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 498,312 shares of the company's stock after selling 56,844 shares during the quarter. Janus Henderson Group PLC owned 0.89% of Enovis worth $21,452,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the company. Ridgewood Investments LLC purchased a new stake in shares of Enovis during the second quarter worth about $44,000. DekaBank Deutsche Girozentrale purchased a new stake in Enovis during the 3rd quarter valued at approximately $55,000. Innealta Capital LLC bought a new stake in shares of Enovis during the second quarter valued at approximately $65,000. Benjamin F. Edwards & Company Inc. raised its position in shares of Enovis by 28.1% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,691 shares of the company's stock valued at $76,000 after buying an additional 371 shares during the last quarter. Finally, FMR LLC lifted its holdings in shares of Enovis by 20.5% in the third quarter. FMR LLC now owns 2,840 shares of the company's stock worth $122,000 after buying an additional 484 shares in the last quarter. 98.45% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have issued reports on ENOV shares. Evercore ISI reduced their price target on shares of Enovis from $62.00 to $58.00 and set an "outperform" rating on the stock in a report on Tuesday, October 1st. JMP Securities assumed coverage on Enovis in a report on Thursday, October 3rd. They issued an "outperform" rating and a $62.00 target price on the stock. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $65.00 target price on shares of Enovis in a research report on Thursday, November 7th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $67.00.

Enovis Trading Down 0.5 %

ENOV traded down $0.25 on Friday, hitting $47.63. The company had a trading volume of 576,995 shares, compared to its average volume of 585,050. The business's fifty day simple moving average is $43.70 and its 200 day simple moving average is $44.70. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. Enovis Co. has a 12-month low of $38.27 and a 12-month high of $65.03. The company has a market cap of $2.66 billion, a PE ratio of -21.75 and a beta of 1.94.

Enovis (NYSE:ENOV - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported $0.73 EPS for the quarter, topping analysts' consensus estimates of $0.62 by $0.11. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The firm had revenue of $505.22 million during the quarter, compared to analysts' expectations of $504.44 million. During the same quarter in the previous year, the business earned $0.56 EPS. The company's quarterly revenue was up 21.0% on a year-over-year basis. Equities research analysts expect that Enovis Co. will post 2.79 EPS for the current year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.